^
Association details:
| Biomarker: | PIK3CA mutation + HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.
Published date:
05/16/2018
Excerpt:
This pre-planned translational analysis aimed to identify potential early predictors for response to neoadjuvant therapy (containing T-DM1 or T) in HER2+/HR+ EBC...PIK3CA mutations were associated both directly (lower pCR) and indirectly (stagnation of CD8 change) with poorer response to neoadjuvant therapy in HER2+/HR+ EBC.
DOI:
10.1200/JCO.2018.36.15_suppl.572
Trial ID:
